Equillium (EQ) Cash from Investing Activities (2018 - 2026)
Equillium's (EQ) quarterly Cash from Investing Activities came in at -$3000.0 in Q1 2026, down 100.07% year-on-year from $4.5 million in Q1 2025, and up 90.62% on a QoQ basis from -$32000.0 in Q4 2025.
Equillium (EQ) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Equillium (EQ) has 9 years of Cash from Investing Activities data on file, last reported at -$3000.0 in Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 100.07% year-over-year to -$3000.0 in Q1 2026; TTM through Mar 2026 was -$35000.0, a 100.17% decrease from a year earlier, with the FY2025 full-year figure at $4.5 million, down 67.68% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$3000.0, up from -$32000.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for EQ reached as high as $15.0 million in Q3 2022 and fell as low as -$25.2 million in Q1 2023.
- Historically, Cash from Investing Activities has averaged $2.1 million across 5 years, with a median of $4.5 million in 2025.
- Across the five-year window, Cash from Investing Activities plunged 346.6% in 2022 and soared 258.81% in 2025, its largest moves.
- Year by year, Cash from Investing Activities stood at $7.0 million in 2022, then plunged by 179.76% to -$5.6 million in 2023, then soared by 207.73% to $6.0 million in 2024, then tumbled by 100.53% to -$32000.0 in 2025, then jumped by 90.62% to -$3000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$3000.0 in Q1 2026, -$32000.0 in Q4 2025, and $4.5 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Equillium | 246.96 Mn | 246.96 Mn | - | -3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,000.00 |
| Mar 31, 2026 | -3,000.00 |
| Dec 31, 2025 | -32,000.00 |
| Dec 31, 2025 | -32,000.00 |
| Mar 31, 2025 | 4.50 Mn |
| Mar 31, 2025 | 4.50 Mn |
| Dec 31, 2024 | 6.00 Mn |
| Dec 31, 2024 | 6.00 Mn |
| Sep 30, 2024 | 12.00 Mn |
| Sep 30, 2024 | 12.00 Mn |
| Jun 30, 2024 | -1.35 Mn |
| Jun 30, 2024 | -1.35 Mn |
| Mar 31, 2024 | -2.83 Mn |
| Mar 31, 2024 | -2.83 Mn |
| Dec 31, 2023 | -5.57 Mn |
| Dec 31, 2023 | -5.57 Mn |
| Sep 30, 2023 | 10.99 Mn |
| Sep 30, 2023 | 10.99 Mn |
| Jun 30, 2023 | 15.00 Mn |
| Jun 30, 2023 | 15.00 Mn |